Microbot Medical Inc.

Equities

MBOT

US59503A2042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.8632 ^USD	-3.12%		-3.01%	-47.37%

Apr. 16	HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating	MT
Mar. 27	Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 17, 2021 at 03:44 pm EDT

Microbot Medical Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 2.392 million compared to USD 2.163 million a year ago. Net loss was USD 2.388 million compared to USD 2.205 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.31 a year ago.

Latest news about Microbot Medical Inc.

HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating	Apr. 16	MT
Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Microbot Medical Submits US FDA Application to Start Human Clinical Trial for Robotic Surgical System	Feb. 05	MT
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US	Feb. 05	CI
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study	Jan. 18	CI
Sector Update: Health Care Stocks Ease Friday Afternoon	Dec. 29	MT
Microbot Medical to Exercise Outstanding Preferred Investment Options for $2.7 Million	Dec. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT
Microbot Medical Says GLP Preclinical Study of Liberty Endovascular Robotic Surgical System Met Objectives; Shares Rise	Dec. 28	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	Dec. 28	MT
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met	Dec. 28	CI
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY Endovascular Robotic Surgical System for Telerobotic	Dec. 14	CI
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study	Dec. 07	CI
Microbot Medical Inc. Announces Executive Changes	Nov. 21	CI
Microbot Medical Files $75 Million Shelf	Nov. 20	MT
Microbot Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process	Nov. 13	CI
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	Nov. 08	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	Nov. 08	MT
Microbot Medical Gets Registered Trademark From US Patent and Trademark Office	Nov. 08	MT
Microbot Medical Inc. Approves Ratification of Brightman Almagor Zohar & Co. as Independent Registered Public Accounting Firm	Nov. 06	CI
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study	23-10-31	CI
Microbot Medical Says Court Dismisses Counterclaim Against Company in Short-Swing Lawsuit	23-10-19	MT
Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System	23-10-17	CI
Microbot Medical Inc. Announces the Resignation of Eyal Morag as Chief Medical Officer, Effective November 29, 2023	23-09-05	CI

Chart Microbot Medical Inc.

Duration

Period

More charts

Company Profile

Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the bodyâs vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8632 USD

Average target price

7 USD

Spread / Average Target

+710.94%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MICROBOT MEDICAL INC.	-47.37%	12.43M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+46.73%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research